United Therapeutics Corporation (NASDAQ:UTHR) Position Lessened by KBC Group NV

KBC Group NV lowered its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 11.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 109,086 shares of the biotechnology company's stock after selling 13,969 shares during the period. KBC Group NV owned about 0.24% of United Therapeutics worth $33,628,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of UTHR. Dunhill Financial LLC lifted its stake in United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after buying an additional 50 shares in the last quarter. Sound Income Strategies LLC purchased a new stake in shares of United Therapeutics in the first quarter valued at $49,000. State of Wyoming acquired a new stake in shares of United Therapeutics during the fourth quarter valued at $62,000. Millstone Evans Group LLC purchased a new stake in United Therapeutics during the 4th quarter worth about $67,000. Finally, Curat Global LLC purchased a new stake in United Therapeutics during the 1st quarter worth about $63,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on UTHR. HC Wainwright reiterated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. JPMorgan Chase & Co. reduced their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Finally, Cantor Fitzgerald initiated coverage on United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $386.15.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, June 26th. The shares were sold at an average price of $285.70, for a total transaction of $3,142,700.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company's stock, valued at $10,508,331.70. This trade represents a 23.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the sale, the chief financial officer directly owned 8,118 shares of the company's stock, valued at $2,641,353.66. The trade was a 59.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 91,681 shares of company stock worth $27,319,919 over the last quarter. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Stock Performance

Shares of UTHR stock traded up $3.08 on Monday, hitting $287.35. The stock had a trading volume of 397,145 shares, compared to its average volume of 445,911. United Therapeutics Corporation has a 52-week low of $250.60 and a 52-week high of $417.82. The firm has a market capitalization of $12.96 billion, a price-to-earnings ratio of 11.47, a P/E/G ratio of 6.22 and a beta of 0.57. The stock's 50 day moving average is $301.12 and its 200-day moving average is $324.60.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same period last year, the firm earned $6.17 earnings per share. The company's revenue was up 17.2% on a year-over-year basis. Equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.